An official website of the United States government
Investigation of Novel Surgical Imaging for Tumor Excision
Trial Status: complete
This is a multi-center, two-arm randomized, blinded pivotal study to demonstrate the
safety and efficacy of the LUM Imaging System (LUM015 imaging agent in conjunction with
the LUM Imaging Device and decision software), in identifying residual cancer in the
lumpectomy bed of female breast cancer patients undergoing breast surgery in order to
assist surgeons in reducing the rates of positive margins.
All enrolled subjects will be injected with LUM015 prior to surgery. Surgeons are blinded
to whether a participant will be randomized into the device arm until after the standard
of care lumpectomy is complete. Participants will then be randomized to receiving the
device. Therapeutic (LUM guided) shaves will be removed based on the guidance of the LUM
Imaging System. Patients will be followed until their first standard of care
post-operative follow-up visit.
Inclusion Criteria
Subjects must have histologically or cytologically confirmed primary invasive breast cancer, ductal carcinoma in situ (DCIS) or primary invasive breast cancer with a DCIS component.
Female, age of 18 years or older.
Subjects must be scheduled for a lumpectomy for a breast malignancy.
Subjects must be able and willing to follow study procedures and instructions.
Subjects must have received and signed an informed consent form.
Subjects must have no uncontrolled serious medical problems except for the diagnosis of breast cancer, as per the exclusion criteria listed below.
Subjects must have organ and marrow function within limits as defined below:
Leukocytes > 3,000/microlitre (mcL).
Platelets > 75,000/mcL
total bilirubin within normal institutional limits
Aspartate aminotransferase (AST (SGOT))/alanine transaminase (ALT (SGPT)) < 2.5 X institutional upper limit of normal
Creatinine ≤ 1.5 mg/dL or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria
Subjects who have been diagnosed with bilateral breast cancer and are undergoing bilateral resection procedure
Subjects who are pregnant. Breastfeeding should be discontinued if the mothers is treated with Pegulicianine (LUM015)
Subjects who are sexually active and not willing/able to use 2 medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015.
Subjects who have taken an investigational drug within 30 days of enrollment.
Subjects who will have administration of methylene blue or any dye for sentinel lymph node mapping on the day of the surgery prior to imaging the lumpectomy cavity with the LUM Imaging Device.
Subjects who have not recovered from adverse events due to other pharmaceutical or diagnostic agents.
Subjects with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 110 mm Hg; those subjects with known hypertension (HTN) should be stable with controlled HTN while under pharmaceutical therapy.
History of allergic reaction to polyethylene glycol (PEG).
History of allergic reaction to any oral or intravenous contrast agents.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, chronic obstructive pulmonary disease (COPD) or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.
HIV-positive individuals on combination antiretroviral therapy are ineligible.
Any subject for whom the investigator feels participation is not in the best interest of the subject.
Subjects undergoing a second lumpectomy procedure because of positive margins in a previous surgery prior to entering this study
Subjects with post-biopsy hematomas greater or equal to 2 cm that are visible on physical exam or detected during pre-operative observations.
Subjects with prior ipsilateral breast cancer surgeries, mastectomies, breast reconstructions or implants.s with prior ipsilateral breast cancer surgeries, mastectomies, breast reconstructions or implants
Subjects with prior ipsilateral reduction mammoplasties (breast reductions) performed less than 2 years prior to enrollment to this study.
Subjects previously treated with systemic therapies to treat the cancer to be removed during this clinical investigation, such as neo-adjuvant chemotherapy or hormonal therapy.
Subjects undergoing breast conserving surgery whose resected specimen (main lump, shaves, or any other resected tissue) will be evaluated with frozen section after the LUM-guided removal of shaves.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03686215.
Locations matching your search criteria
United States
California
Palo Alto
Stanford Cancer Institute Palo Alto
Status: Active
Name Not Available
North Carolina
Durham
Duke University Medical Center
Status: Active
Name Not Available
All subjects will be injected with LUM015. The injection of the study drug will occur 2-6
hours prior to surgery at a dose of 1.0 mg/kg. Surgeons will complete the standard of
care lumpectomy. Prior to removing any shaves as part of the standard of care, the
surgeon will use the LUM Imaging System to scan and image the cavity where shaves will be
obtained. The system will not provide guidance. The intent of the standard of care
lumpectomy procedure is to achieve negative margins.
Randomization of whether the patient will receive the device will be revealed after the
completion of the standard of care lumpectomy. If the patient is randomized to the
non-device arm, then the surgeon will complete the surgery per their standard practice.
If the patient is randomized to the device arm, the surgeon will use the LUM Imaging
Device to scan inside the lumpectomy cavity to indicate areas that may contain residual
tumor. If the imaging system identifies that there may be cancer cells remaining in the
lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process
will be continued until a negative reading from the device is obtained or a maximum of 2
shaves of additional tissue has been removed in each orientation.
Study treatment ends when the surgery is completed. All patients will continue their
enrollment in the study until their first follow-up visit and they will continue to be
followed until the medical team determines no further surgical intervention is required.
Patients who have consented to completing Quality of Life Questionnaires will be in the
study until the schedule of questionnaires is complete. Patients with adverse events that
are determined to be possibly related to the LUM Imaging System will be followed until
